ArticleAnnals of medicine2026

Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system.

Rui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.